Profound Medical Corp (PROF) reports a 43% revenue increase and global expansion, while addressing operational challenges and aiming for cash flow positivity.

The only approved gene therapy for RP today targets a single gene RPE65, which accounts for just 1% to 2% of the total RP patient population. We believe OCU400 has significantly wider commercial ...

And as we lean in further, AI is strengthening our advantage, enabling significantly more automation and value for our customers, embedding our products more deeply into their daily operations and ...